Gene expression significance in personalized medicine of non-small cell lung cancer and gene expression analyzing platforms

Current Drug Metabolism

Volumn 12, Issue 5, 2011, Pages 455-459

  Zhang, Li ^a   Yang, Huiyi ^b   Xu, Jiasen ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b SurExam Bio Tech Co Ltd   (China)

Author keywords

BDNA; Gene expression; Immunohistochemistry; Predictive biomarkers; Quantitative assays; RT PCR

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PEMETREXED; UNCLASSIFIED DRUG;

ARTICLE; DNA REPAIR; DNA SYNTHESIS; ERCC1 GENE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MITOSIS; ONCOGENE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RRM1 GENE; STMN1 GENE; TECHNOLOGY; TUBB3 GENE; TYMS GENE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 79955686865     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920011795495303     Document Type: Article

References (71)

1. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics. 2002. CA Cancer J. Clin., 2005, 55, 74-108.
2. Herbst, R. S.; Heymach, J. V.; Lippman, S. M. Lung cancer. N. Engl. J. Med., 2008, 359, 1367-1380.
3. Ettinger, D. S. NCCN Clinical Practice Guidelines in Oncology for Non-small-cell lung cancer. V.2. ed.; 2010.
4. Kwon, H.-C.; Roh, M.; Oh, S.; Kim, S.-H.; Kim, M.; Kim, J.-S.; Kim, H.-J. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5- fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann. Oncol., 2007, 18 (3), 504-509. (Pubitemid 46359630)
5. Bellmunt, J.; Paz-Ares, L.; Cuello, M.; Cecere, F.; Albiol, S.; Guillem, V.; Gallardo, E.; Carles, J.; Mendez, P.; Cruz, J. d. l.; Taron, M.; Rosell, R.; Baselga, J. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol., 2007, 18 (3), 522-528. (Pubitemid 46359633)
6. Bepler, G.; Kusmartseva, I.; Sharma, S.; Gautam, A.; Cantor, A.; Sharma, A.; Simon, G. RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non-Small-Cell Lung Cancer. J. Clin. Oncol., 2006, 24 (29), 4731-4737. (Pubitemid 46646245)
7. Lord, R. V. N.; Brabender, J.; Gandara, D.; Alberola, V.; Camps, C.; Domine, M.; Cardenal, F.; Sánchez, J. M.; Gumerlock, P. H.; Tarón, M.; Sánchez, J. J.; Danenberg, K. D.; Danenberg, P. V.; Rosell, R. Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer. Clin. Cancer Res., 2002, 8, 2286-2291. (Pubitemid 34753602)
8. Dabholkar, M.; Bostick-Bruton, F.; Weber, C.; Bohr, V. A.; Egwuagu, C.; Reed, E. ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients. J. Natl. Cancer Inst., 1992, 84, 1512-1517.
9. Metzger, R.; Leichman, C.; Danenberg, K.; Danenberg, P.; HJ Lenz, K. H.; Groshen, S.; Salonga, D.; Cohen, H.; Laine, L.; Crookes, P.; Silberman, H.; Baranda, J.; Konda, B.; Leichman, L. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol., 1998, 16, 309-316. (Pubitemid 28041614)
10. Olaussen, K. A.; Dunant, A.; Fouret, P.; Brambilla, E.; André, F.; Haddad, V.; Taranchon, E.; Filipits, M.; Pirker, R.; Popper, H. H.; Stahel, R.; Sabatier, L.; Pignon, J.-P.; Tursz, T.; Chevalier, T. L.; Soria, J.-C. DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. N. Engl. J. Med., 2006, 355, 983-991. (Pubitemid 44343542)
11. Zheng, Z.; Chen, T.; Li, X.; Haura, E.; Sharma, A.; Bepler, G. DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer. N. Engl. J. Med., 2007, 356, 800-808. (Pubitemid 46294612)
12. Rosell, R.; Danenberg, K. D.; Alberola, V.; Bepler, G.; Sanchez, J. J.; Camps, C.; Provencio, M.; Isla, D.; Taron, M.; Diz, P.; Artal, A. Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin- Treated Advanced Non-Small Cell Lung Cancer Patients. Clin. Cancer Res., 2004, 10, 1318-1325. (Pubitemid 38365223)
13. Fujiia, T.; Toyookaa, S.; Ichimurab, K.; Fujiwarac, Y.; Hottac, K.; Soha, J.; Suehisaa, H.; Kobayashia, N.; Aoea, M.; Yoshinob, T.; Kiurac, K.; Datea, H. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-smallcell lung cancer. Lung Cancer, 2008, 59 (3), 377-384.
14. Ettinger, D. S. NCCN Clinical Practice Guidelines in Oncology for Non-small-cell lung cancer. V.2. ed.; 2009.
15. Cobo, M.; Isla, D.; Massuti, B.; Montes, A.; Sanchez, J. M.; Provencio, M.; Viñolas, N.; Paz-Ares, L.; Lopez-Vivanco, G.; Muñoz, M. A.; Felip, E.; Alberola, V.; Camps, C.; Domine, M.; Sanchez, J. J.; Sanchez-Ronco, M.; Danenberg, K.; Taron, M.; Gandara, D.; Rosell, R. Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer. J. Clin. Oncol., 2007, 25, 2747-2754. (Pubitemid 47123183)
16. Soria, J.-C. ERCC1-Tailored Chemotherapy in Lung Cancer: The First Prospective Randomized Trial. J. Clin. Oncol., 2007, 25 (19), 2648-2649. (Pubitemid 47123168)
17. Xue, L.; Zhou, B.; Liu, X.; Qiu, W.; Jin, Z.; Yen, Y. Wild-Type p53 Regulates Human Ribonucleotide Reductase by Protein- Protein Interaction with p53R2 as well as hRRM2 Subunits Cancer Res., 2003, 63, 980-986. (Pubitemid 36278428)
18. Davidson, J. D.; Ma, L.; Flagella, M.; Geeganage, S.; Gelbert, L. M.; Slapak, C. A. An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines Cancer Res., 2004, 64, 3761-3766. (Pubitemid 38697284)
19. Rosell, R.; Scagliotti, G.; Danenberg, K. D.; Lord, R. V.; Bepler, G.; Novello, S.; Cooc, J.; Crinò, L.; nchez, J. J. S.; Taron, M.; Boni, C.; Marinis, F. D.; Tonato, M.; Marangolo, M.; Gozzelino, F.; Costanzo, F. D.; Rinaldi, M.; Salonga, D.; Stephens, C. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene, 2003, 22, 3548-3553. (Pubitemid 36765314)
20. Bepler, G.; Li, X.; Schell, M.; Zheng, Z.; Boulware, D.; Obasaju, C. K.; Reynolds, C. Predictive value of RRM1 and ERCC1 protein levels in a prospective community-based trial of gemcitabine/ carboplatin (GC) vs gemcitabine (G) alone. J. Clin. Oncol., 2008, 26 (May 20 suppl), abstr 8033.
21. Reynolds, C.; Obasaju, C.; Schell, M. J.; Li, X.; Zheng, Z.; Boulware, D.; Caton, J. R.; DeMarco, L. C.; O'Rourke, M. A.; Wright, G. S.; Boehm, K. A.; Asmar, L.; Bromund, J.; Peng, G.; Monberg, M. J.; Bepler, G. Randomized Phase III Trial of Gemcitabine- Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non-Small-Cell Lung Cancer. J. Clin. Oncol., 2009, 27 (34), 5808-5815.
22. Kakimoto, M.; Uetake, H.; Osanai, T.; Shirota, Y. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Letters, 2005, 223, 103-111. (Pubitemid 40693714)
23. Oguri, T.; Achiwa, H.; Bessho, Y.; Muramatsu, H.; Maeda, H.; Niimi, T.; Sato, S.; Ueda, R. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer, 2005, 49 (3), 345-351. (Pubitemid 41139147)
24. Johnston, P. G.; Lenz, H.-J.; Leichman, C. G.; Danenberg, K. D.; Allegra, C. J.; Danenberg, P. V.; Leichman, L. Thymidylate Synthase Gene and Protein Expression Correlate and Are Associated with Response to 5-Fluorouracil in Human Colorectal and Gastric Tumors. Cancer Research, 1995, 55, 1407-1412.
25. Yasumatsua, R.; Nakashimaa, T.; Uryua, H.; Ayadaa, T. Correlations between Thymidylate Synthase Expression and Chemosensitivity to 5-Fluorouracil, Cell Proliferation and Clinical Outcome in Head and Neck Squamous Cell Carcinoma. Chemotherapy, 2009, 55, 36-41.
26. Shintania, Y.; Ohtaa, M.; Hirabayashia, H.; Tanakab, H. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. Lung Cancer, 2004, 45 (2).
27. Eismann, U.; Oberschmidt, O.; Ehnert, M.; Fleeth, J., Thymidylate Synthase Gene Expression in Solid Tumors predicts for Response to Pemetrexed in vitro. In 2006 ASCO Annual Meeting, 2006.
28. Gomez, H. L.; Santillana, S. L.; Vallejos, C. S.; Velarde, R. A Phase II Trial of Pemetrexed in Advanced Breast Cancer: Clinical Response and Association with Molecular Target Expression Clinical Cancer Research, 2006, 12, 832-838.
29. Silva, A. G.; Cole, J. T. NSCLC in Louisiana: Thymidylate synthase and pemetrexed therapy. J. Clin. Oncol., 2010, 28, abr.18142.
30. Changa, M. H.; Ahna, J. S.; Leea, J.; Kima, K. H.; Parka, Y. H.; Hanb, J.; Ahna, M.-J.; Parka, K. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer Lung Cancer, 2010, article in press.
31. Niedernhofer, L. J.; Bhagwat, N.; Wood, R. D. ERCC1 and Non- Small-Cell Lung Cancer. N. Engl. J. Med., 2007, 356 (24), 2538-2541.
32. Takeda, M.; Okamoto, I.; Fukuoka, M.; Nakagawa, K. Association of thymidylate synthase (TS) expression with response to S-1 plus carboplatin (CBDCA) in non-small cell lung cancer (NSCLC) patients (pts). J. Clin. Oncol., 2010, 28, abr.21025.
33. Noro, R.; Miyanaga, A.; Minegishi, Y.; Okano, T.; Seike, M.; Soeno, C.; Kataoka, K.; Matsuda, K.; Yoshimura, A.; Gemma, A. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21 expression. Cancer Sci., 2010, artical in press.
34. Leandro-García, L. J.; Leskelä, S.; Landa, I.; Montero-Conde, C.; López-Jiménez, E.; Letón, R.; Cascón, A.; Robledo, M.; Rodríguez- Antona, C. Tumoral and tissue-specific expression of the major human -tubulin isotypes. Cytoskeleton, 2010, 67 (4), 214-223.
35. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4, 253-265. (Pubitemid 38525281)
36. Lu, Q.; Luduena, R. F. Removal of βIII Isotype Enhances Taxol Induced Microtubule Assembly. Cell Struct. Funct., 1993, 18, 173-182. (Pubitemid 23307472)
37. Kamath, K.; Wilson, L.; Cabral, F.; Jordan, M. A. βIII-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability. J. Biol. Chem., 2005, 280, 12902-12907.
38. Brattsand, G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br. J. Cancer, 2000, 83 (3), 311-318. (Pubitemid 30453569)
39. Iwataa, T.; Namikawa, K.; Honma, M.; Morid, N.; Yachiku, S.; Kiyama, H. Increased expression of mRNAs for microtubule disassembly molecules during nerve regeneration Mol. Brain Res., 2002, 102, 105-109. (Pubitemid 34607747)
40. Sève, P.; Mackey, J.; Isaac, S.; Trèdan, O.; Souquet, P.-J.; Pèrol, M.; Lai, R.; Voloch, A.; Dumontet, C. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol. Cancer Ther., 2005, 4 (12), 2001-2007. (Pubitemid 43056983)
41. Sève, P.; Isaac, S.; Trédan, O.; Souquet, P.-J.; Pachéco, Y.; Pérol, M.; Lafanéchère, L.; Penet, A.; Peiller, E.-L.; Dumontet, C. Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine- Based Chemotherapy Clin. Cancer Res., 2005, 11, 5481-5486. (Pubitemid 41060824)
42. Sève, P.; Reimand, T.; Dumontetabc, C. The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer, 2010, 67 (8), 136-143.
43. Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer, 2010, 10, 194-204.
44. Wolff, A. C.; Hammond, M. E. H.; Schwartz, J. N.; Hagerty, K. L.; D. Craig Allred; Cote, R. J.; Dowsett, M.; Fitzgibbons, P. L.; Hanna, W. M.; Langer, A.; McShane, L. M.; Paik, S.; Pegram, M. D.; Perez, E. A.; Press, M. F.; Rhodes, A.; Sturgeon, C.; Taube, S. E.; Tubbs, R.; Vance, G. H.; Vijver, M. v. d.; Wheeler, T. M.; Hayes, D. F. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J. Clin. Oncol., 2007, 25, 118-145. (Pubitemid 350003059)
45. Hammond, M. E. H.; Hayes, D. F.; Dowsett, M.; Allred, D. C.; Hagerty, K. L.; Badve, S.; Fitzgibbons, P. L.; Francis, G.; Goldstein, N. S.; Hayes, M.; Hicks, D. G.; Lester, S.; Love, R.; Mangu, P. B.; McShane, L.; Miller, K.; Osborne, C. K.; Paik, S.; Perlmutter, J.; Rhodes, A.; Sasano, H.; Schwartz, J. N.; Sweep, F. C. G.; Taube, S.; Torlakovic, E. E.; Valenstein, P.; Viale, G.; Visscher, D.; Wheeler, T.; Williams, R. B.; Wittliff, J. L.; Wolff, A. C. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J. Clin. Oncol., 2010, 28 (16), 2784-2798.
46. Moeder, C. B.; Giltnane, J. M.; Moulis, S. P.; Rimm, D. L. Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol. Biol., 2009, 520, 163-175.
47. Lewis, F.; Maughan, N. J.; Smith, V.; Hillan, K.; Quirke, P. Unlocking the archive - gene expression in paraffin-embedded tissue J. Pathol., 2001, 195, 66-71. (Pubitemid 32899046)
48. Godfrey, T. E.; Kim, S.-H.; Chavira, M.; Ruff, D. W.; Warren, R. S.; Gray, J. W.; Jensen, R. H. Quantitative mRNA Expression Analysis from Formalin-Fixed, Paraffin-Embedded Tissues Using 5' Nuclease Quantitative Reverse Transcription-Polymerase Chain Reaction J. Mol. Diagn., 2000, 2, 84-91.
49. Cronin, M.; Pho, M.; Dutta, D.; Stephans, J. C.; Shak, S.; Kiefer, M. C.; Esteban, J. M.; Baker, J. B. Measurement of Gene Expression in Archival Paraffin-Embedded Tissues: Development and Performance of a 92-Gene Reverse Transcriptase-Polymerase Chain Reaction Assay Am. J. Pathol, 2004, 164, 35-42. (Pubitemid 38364587)
50. Finke, J., R. ; Fritzen, P.; Ternes, W. L.; Dolken., G. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. BioTechniques., 1993, 14, 448-453.
51. Masuda, N.; Ohnishi, T.; Kawamoto, S.; Monden, M.; Okubo, K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res, 1999, 27, 4436-4443. (Pubitemid 29533185)
52. Bresters, D.; Schipperb, M. E. I.; Reesinka, H. W.; Boeser- Nunninka, B. D. M.; Cuypersa, H. T. M. The duration of fixation influences the yield of HCV cDNA-PCR products from formalinfixed, paraffin-embedded liver tissue. J. Virol. Methods, 1994, 48, 267-272. (Pubitemid 24246641)
53. Macabeo-Ong, M.; Ginzinger, D. G.; Dekker, N.; McMillan, A.; Regezi, J. A.; Wong, D. T. W.; Jordan, R. C. K. Effect of Duration of Fixation on Quantitative Reverse Transcription Polymerase Chain Reaction Analyses. Mod. Pathol., 2002, 15, 979-987.
54. Yang, W.; Maqsodi, B.; Ma, Y.; Bui, S.; Crawford, K. L.; McMaster, G. K.; Witney, F.; Luo, Y. Direct quantification of gene expression in homogenates of formalin-fixed, paraffin-embedded tissues BioTechniques, 2006, 40, 481-486. (Pubitemid 46534929)
55. Canales, R. D.; Luo, Y.; Willey, J. C.; Austermiller, B.; Barbacioru1, C. C.; Boysen, C.; Hunkapiller, K.; Jensen, R. V.; Knight, C. R.; Lee, K. Y.; Ma, Y.; Maqsodi, B.; Papallo, A.; Peters, E. H.; Poulter, K.; Ruppel, P. L.; Samaha, R. R.; Shi, L.; Yang, W.; Zhang, L.; Goodsaid, F. M. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat. Biotechnol., 2006, 24 (9), 1115-1122. (Pubitemid 44359723)
56. VanGuilder, H. D.; Vrana, K. E.; Freeman, W. M. Twenty-five years of quantitative PCR for gene expression analysis. BioTechniques, 2008, 44, 619-626. (Pubitemid 351656280)
57. Gaunt, E. R.; Hardie, A.; Claas, E. C.; Simmonds, P.; Templeton, K. E. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63 and OC43 detected over 3 years using a novel multiplex real-time PCR J. Clin. Microbiol. , 2010, published online ahead of print.
58. Bustin, S. A. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J. Mol. Endocrinol., 29, 23-39.
59. Nolan, T.; Hands, R. E.; Bustin, S. A. Quantification of mRNA using real-time RT-PCR. Nature Protocols, 2006, 1, 1559-1582.
60. Willey, J. C.; Crawford, E. L.; Jackson, C. M.; Weaver, D. A.; Hoban, J. C.; Khuder, S. A.; DeMuth, J. P. Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. Am. J. Respir. Cell Mol. Biol., 1998, 19, 6-17. (Pubitemid 128354936)
61. Rots, M. G.; Willey, J. C.; Jansen, G.; Zantwijk, C. H. V.; Noordhuis, P.; DeMuth, J. P.; Kuiper, E.; Veerman, A. J. P.; Pieters, R.; Peters, G. J. mRNA expression levels of methotrexate resistance- related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia, 2000, 14 (12), 2166-2175. (Pubitemid 32042257)
62. Mullins, D. A. N.; LCrawford, E.; Khuder, S. A.; Hernandez, D.- A.; Yoon, Y.; Willey, J. C. CEBPG transcription factor correlates with antioxidant and DNA repair genes in normal bronchial epithelial cells but not in individuals with bronchogenic carcinoma. BMC Cancer, 2005, 5, 141.
63. Flagella, M.; Bui, S.; Zheng, Z.; Nguyen, C. T.; Aiguo Zhang; Pastor, L.; Ma, Y.; Yang, W.; Crawford, K. L.; McMaster, G. K.; Witney, F.; Luo, Y. A multiplex branched DNA assay for parallel quantitative gene expression profiling. Anal. Biochem., 2006, 352, 50-60.
64. Cleveland, W. S. Robust locally weighted regression and smoothing scatter plots. J. Am. Stat. Assoc., 1979, 74, 829-836.
65. Stenman, J.; Orpana, A. Accuracy in amplification. Nat. Biotechnol., 2001, 19, 1011-1012.
66. Elbeik, T.; Surtihadi, J.; Destree, M.; Gorlin, J.; Holodniy, M.; Jortani, S. A.; Kuramoto, K.; Ng, V.; Jr., R. V.; Valsamakis, A.; Terrault, N. A. Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA). . J. Clin. Microbiol. , 2004, 42, 563-569. (Pubitemid 38222629)
67. Paik, S.; Kim, C.; Wolmark, N. HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer. N. Engl. J. Med., 2008, 358 (13), 1410-1411.
68. Miao, Z.; Luker, K. E.; Summers, B. C.; Berahovich, R.; Bhojani, M. S.; Rehemtulla, A.; Kleer, C. G.; Essner, J. J.; Nasevicius, A.; Luker, G. D.; Howard, M. C.; Schall, T. J. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. P. Natl. Acad. Sci. USA, 2007, 104 (40), 15735-15740. (Pubitemid 350035369)
69. Lee, C.J.; Seth, G.; Tsukuda, J.; Hamilton, R.W. A clone screening method using mRNA levels to determine specific productivity and product quality for monoclonal antibodies. Biotechnol. Bioeng., 2009, 102 (4), 1107-1118.
70. Zhang, Y.K.J.; Yeager, R.L.; Klaassen, C.D. Circadian Expression Profiles of Drug-Processing Genes and Transcription Factors in Mouse Liver. Drug Metab. Dispos., 2009, 37 (1), 106-115.
71. Zhou, Q.; He, J.; Yang, H.; Luo, X.; Xu, J.; Ren-Heidenreich, L. RNA expression profiling of ERCC1, BRCA1, TUBB3, and STMN1 in non-small cell lung cancer by a multiplex branched DNA liquidchip technology (MBL) for predicting the efficacy of chemotherapy. J. Clin. Oncol., 2010, 28, abstr e21020.